Core Viewpoint - The successful IPO of Zhuozheng Medical on February 6, 2026, highlights the growth potential of the mid-to-high-end healthcare service market in China, despite emerging challenges in revenue growth and financial stability [2][20]. IPO Details - Zhuozheng Medical was listed on the Hong Kong Stock Exchange with an issue price of HKD 59.9 per share, opening at HKD 81 and reaching HKD 88.2 on the first day, marking a 47.25% increase and a market capitalization of approximately HKD 50.22 billion [3]. - The IPO raised around HKD 284 million by issuing 4,750,000 shares, with a high subscription rate of 2730.73 times for public offerings and 5.79 times for international offerings [4]. Investor Composition - The cornerstone investor lineup includes notable figures from technology, healthcare, and internet sectors, enhancing Zhuozheng Medical's narrative of integrating healthcare services with technological capabilities [5]. - Tencent is a significant institutional investor, holding approximately 20% of the shares, which supports the company's digital operations and user system development [5]. Market Position - Established in 2012, Zhuozheng Medical focuses on the mid-to-high-end healthcare market, primarily serving affluent consumers who prefer personalized medical services. It ranks first and second among private mid-to-high-end comprehensive medical service groups in China based on city coverage and patient visits [8]. Membership and Retention Metrics - As of August 31, 2025, Zhuozheng Medical had 116,500 member accounts, with renewal rates increasing from 42% in 2022 to 67% in 2025, and patient return rates rising from 75.7% to 82.7% in the same period [13]. - The company maintains low marketing expenses, with sales expenditure as a percentage of revenue significantly below the industry average [14]. Revenue Growth and Challenges - Zhuozheng Medical's revenue grew from CNY 473 million in 2022 to CNY 959 million in 2024, with a compound annual growth rate of 42.2%. However, growth in patient visits has slowed, with a notable drop in revenue contribution from first-tier cities [15][16]. - The company achieved profitability in 2024 with an adjusted net profit of CNY 10.7 million, but faces high debt levels, with a debt-to-asset ratio exceeding 227% in recent years [17]. Technology Integration - The company plans to leverage artificial intelligence to enhance service efficiency, although online medical services have not yet become a significant growth driver, with a decline in online service visits noted [19]. Future Outlook - Zhuozheng Medical's IPO success reflects the viability of its "family membership + multi-specialty" healthcare model, but ongoing monitoring of its operational performance post-IPO is crucial due to slowing growth in core markets and high debt pressures [20].

来源：直通IPO，文/韩文静 2月6日，卓正医疗在港交所挂牌上市，此次发行价为59港元/股，开盘涨37.3%至81港元/股，总市值52.86亿港元。截至当日收盘，卓正医疗每股涨13.36%至 67.9港元，总市值43.72亿。 卓正医疗由王志远创立，定位于中高端医疗服务市场的私立医疗机构。卓正医疗在招股书中称，其目标客群是具有较强购买力及偏好更个性化护理的大众富 裕人群，即人均年可支配收入超过20万元的群体。 2012年，卓正医疗通过在深圳的首家建筑面积约50平方米的诊所开展门诊服务。2015年，公司通过在广州及北京成立首批门诊，扩大地理覆盖范围。2018 年，公司成立首家建筑面积超过1000平方米且拥有超过五个科室的医疗服务机构。2021年，公司在新加坡成立首家海外诊所。 | 今井 | 81.000 | | 最高 | 90.850 | | 成交量 | | --- | --- | --- | --- | --- | --- | --- | | 昨收 | 59.900 | | 最低 | 65.150 | | 成交额 | | 换手率 | 3.75% | | 市盈(TTM) | 34.44 | | 总市值 | | ...

Core Viewpoint - The initial public offering (IPO) of Zhuozheng Medical experienced significant volatility, with the stock price rising sharply before closing with a modest gain, indicating mixed investor sentiment and highlighting the challenges faced by the company in maintaining investor confidence [1] Company Overview - Zhuozheng Medical, established in 2012, is a private high-end comprehensive medical service provider focusing on the mid-to-high-end medical service market, offering a wide range of specialties including pediatrics, dentistry, ophthalmology, dermatology, ENT, surgery, gynecology, and internal medicine [3] - The company aims to meet diverse medical needs through close collaboration among specialists, enhancing patient satisfaction and creating referral opportunities [3] Financial Performance - Zhuozheng Medical reported a net profit of 0.83 billion yuan for the period ending August 31, 2025, marking its first true profitability driven by core operations, with operating profit reaching 0.13 billion yuan after excluding the impact of convertible redeemable preferred shares [7] - Despite the recent profitability, the company has faced continuous operating losses from 2021 to 2024, with operating profits remaining negative during this period, indicating a fragile financial foundation [6][8] Market Position and Competition - Zhuozheng Medical holds a 2.0% market share in China's private high-end comprehensive medical service sector, ranking as the third-largest provider based on 2024 revenue [3] - The company faces intense competition from established players like United Family Healthcare and Jiayuan Healthcare, which have more extensive networks and resources, posing significant challenges for Zhuozheng Medical's growth and market positioning [10][11] Investment and Market Sentiment - The IPO attracted significant interest, with a 2730 times oversubscription during the public offering phase, reflecting strong enthusiasm from retail investors and confidence from institutional investors [5] - The presence of notable cornerstone investors, including Tencent and various industry capital firms, underscores the market's recognition of Zhuozheng Medical's business model and growth potential [4]

Core Viewpoint -卓正医疗控股有限公司 (卓正医疗) successfully listed on the Hong Kong Stock Exchange, closing at HKD 67.90, a 13.36% increase from its final offering price of HKD 59.90 [1][6]. Group 1: Offering Details - The total number of shares offered globally was 4,750,000, with 475,000 shares allocated for public offering in Hong Kong and 4,275,000 shares for international offering [2]. - The total proceeds from the offering amounted to HKD 284.53 million, with net proceeds after estimated listing expenses of HKD 208.86 million [6][5]. Group 2: Use of Proceeds - The net proceeds will be used to build a professional talent pool for medical AI applications, enhance internal IT systems, upgrade existing medical facilities, establish new ones, and acquire well-performing medical institutions in major cities [6][7]. Group 3: Business Overview - 卓正医疗 operates 19 medical service institutions in China and four general practice clinics in Singapore, focusing on private healthcare services [7]. - Revenue projections for the years ending December 31 are as follows: RMB 473.2 million in 2022, RMB 690.4 million in 2023, and RMB 958.6 million in 2024, with net losses of RMB -221.5 million, -353.2 million, and a projected profit of RMB 80.2 million in 2024 [7][8]. Group 4: Financial Performance - Adjusted net losses for 2022 and 2023 were RMB 123.0 million and RMB 43.6 million, respectively, while adjusted net profits are projected for 2024 and the first eight months of 2025 [10][11]. - Operating cash flows for the years ending December 31 are projected to be RMB 6.9 million in 2022, RMB 123.8 million in 2023, and RMB 171.3 million in 2024 [12]. Group 5: Debt and Financial Challenges - As of the end of 2024, 卓正医疗's total liabilities reached RMB 30.85 billion, with current liabilities increasing from RMB 22.62 billion in 2022 to RMB 27.04 billion by August 2025 [13].

2月6日，新股市场迎来"三箭齐发"，卓正医疗（02677.HK）、大族数控（03200.HK）、牧原股份（02714.HK）联袂登陆港股市场。 其中，卓正医疗迎来大涨，截至发稿时间股价升逾34%，表现强于另外两只新股。 从日前招股阶段的表现来看，香港公开发售方面，卓正医疗获2730.73倍认购，公开发售的发售股份最终数目为47.50万股股份，占发售股份总数的约 10.00%。有效申请数目约为14.78万份，受理申请数目9500份。 此外，国际配售方面，卓正医疗获5.79倍认购，国际发售股份最终数目为427.50万股股份，相当于发售股份总数的90.00%。 若希望进一步了解卓正医疗的基本面解读及业务线分析，可查阅财华社过往相关报道《一图解码：卓正医疗二次递表港交所 私立中高端医疗服务商 业绩扭 亏》。 卓正医疗每股发售价为59.90港元，最终净筹2.09亿港元。每手50股，截至发稿时间，其股价现为80.40港元，不计手续费，一手赚1025港元。 在此次发行中，卓正医疗获得了金域检验、明略科技-W（02718.HK）等四位基石投资者的支持，目前已经浮盈不少。 卓正医疗是中国的私立医疗服务机构，战略重点是服务中高端 ...

天图投资的第三只健康医疗基金正在募集中。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，卓正医疗控股有限公司（以下简称"卓正医疗"）于2026年2月6日以"2677"为 股票代码在港交所主板挂牌上市。 作为覆盖中国城市数量最多的私立中高端综合医疗服务机构集团，卓正医疗自成立以来已获得天图投 资、经纬创投、富德生命人寿、前海母基金、中金资本、水木基金、H Capital、浅石创投、华林证 券等知名机构的投资。 其中， 天图投资于2017年领投了卓正医疗的C轮融资，并全程陪伴其发展。IPO前，天图投资是卓 正医疗主要机构投资方，天图投资合伙人魏国兴担任卓正医疗非执行董事。 事实上，天图投资持续关注医疗健康领域投资机遇，较早敏锐捕捉到居民生活水平稳步提升将推动医 疗服务高品质需求这一趋势，研判中高端私立医疗服务赛道厚雪长坡具备长期投资价值，曾先后成功 投资了慈铭体检、凤凰医疗、伊美尔等医疗健康服务机构。 在这一背景下， 魏国兴在卓正医疗成立一年后注意到了这只"有理想又认真做事"的团队，并很快通 过微博私信主动联系到了创始团队，卓正回归医疗本源的理念和坚 ...

Core Viewpoint - Zhuozheng Medical (02677) has successfully listed, pricing each share at HKD 59.9, with a total issuance of 4.75 million shares, raising approximately HKD 209 million in net proceeds. The stock has surged by 35.23% to HKD 81 at the time of reporting, with a trading volume of HKD 71.1362 million [1] Company Overview - Zhuozheng Medical is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market, targeting affluent individuals who prefer personalized care [1] - According to Frost & Sullivan, Zhuozheng Medical is the third-largest private mid-to-high-end comprehensive healthcare service provider in China, holding a market share of 2.0% based on projected revenues for 2024 [1] Service Model - The company adopts a holistic medical approach, integrating both physical and online healthcare services through a family medical model [1] - Zhuozheng Medical offers a range of specialties including pediatrics, dentistry, ophthalmology, dermatology, ENT, surgery, gynecology, and internal medicine, facilitating close collaboration among specialists to meet diverse medical needs of patients and their families [1] - This integrated approach aims to enhance patient satisfaction and create opportunities for cross-specialty referrals [1]

Core Viewpoint - China’s private healthcare service provider, Zhuozheng Medical (2677.HK), is set to list in Hong Kong on February 6, with its dark pool trading showing a significant increase of 57.01% from the IPO price, indicating strong market interest and potential for growth [1][2]. Group 1: Company Overview - Zhuozheng Medical positions itself as the "Costco" of health service consumption, focusing on high-quality, cost-effective service experiences for its members [1]. - The company has developed a health service ecosystem centered around "super users," emphasizing high-frequency health service consumption through a multi-specialty family model [1]. - Zhuozheng Medical aims to break the traditional low-frequency consumption model of single-specialty medical institutions, achieving high repurchase rates and user loyalty [1]. Group 2: Market Trends - The "self-care economy" is reshaping the market, with consumers increasingly prioritizing emotional satisfaction and quality experiences, leading to sustained growth in health and wellness investments [1]. - The health service sector is entering a golden development period, driven by rising consumer demand for quality health services [1]. Group 3: Investment Details - Zhuozheng Medical's IPO has attracted cornerstone investors including Health Vision, Kingmed Diagnostics, Minglue Technology, and Galaxy Dynasty, owned by He Xiaopeng, co-founder of Xiaopeng Motors [2]. - The stock closed at 94.05 HKD in dark pool trading, significantly above the IPO price of 59.9 HKD, reflecting strong investor confidence [2].

私立中高端综合医疗服务机构卓正医疗（02677)将于2月6日(星期五)在港交所挂牌，海通国际和浦银国际为联席保荐人。公司曾三次在港交所申请上市，此 前曾于2024年5月16日、2025年3月18日向港交所递交过上市申请，最近一次递表为2025年11月5日。 富途证券暗盘最新交易显示报价98.8港元，较招股价59.9港元上涨64.94%，每手50股，不计手续费，每手赚1945港元；富途证券暗盘显示公司股价一度涨至 122.9港元，较招股价59.9港元最高上涨105%，每手50股，不计手续费，每手最高赚3150港元。截止发稿，卓正医疗暗盘最新价98.8港元，涨幅64.94%，总 市值63.61港元。 招股书显示，Cheuk Sing Ho有七名股东，即王志远先生、另外两名董事施翼先生及张向东先生、两名高级管理层朱岩医生及周方先生以及另外两名个人张 东生先生及赵瑜女士，彼等分别持有39.1%、 18.4%、2.2%、9.2%、5.1%、1.1%及24.9%的股权。根据Cheuk Sing Ho协议，王志远先生(作为Cheuk Sing Ho的 唯一董事)拥有就该公司所有事宜代表Cheuk Sing Ho作出决定及投 ...

卓正医疗对标Costco打造一站式家庭健康服务中心，通过会员制、高性价比、精选服务品类形成正向增 长飞轮。不靠医保不投营销，凭高价值会员生态+AI赋能领跑行业，业绩实现逆势增长。腾讯领衔豪华 股东阵容，何小鹏及多家腾讯系AI企业参与基石。 招股书显示，卓正医疗本次计划全球发售475万股，其中香港公开发售占一成，发售价为57.7港元-66.6 港元。 1月29日至2月3日，中国健康服务消费新势力品牌卓正医疗(2677.HK)面向市场公开招股。据悉，截至今 日早间，市场认购反响热烈，融资认购额已累计达353亿港元，约超购1118倍。公司预期将于2月6日在 港交所上市买卖 ...